Company profile
Microbot Medical
Microbot Medical develops robotic systems for endovascular procedures. Its LIBERTY robotic platform is designed to let physicians remotely control single-u...
Facts
- Segment
- SURGICAL
- Country
- United States
- Headquarters
- Hingham, MA
- Ticker
- MBOT
- Website
- https://www.microbotmedical.com/
About Microbot Medical
Microbot Medical develops LIBERTY, a remotely operated robotic system for peripheral endovascular procedures. A physician uses a compact controller to manipulate compatible guidewires and catheters from outside the immediate radiation field, while a single-use robotic drive unit mounts beside the patient and interfaces with conventional procedure-room equipment.
The system received US FDA clearance in 2025 and entered a limited commercial release followed by a broader US launch in 2026. Hospitals use LIBERTY in vascular interventions without installing a large fixed robotic console, and the disposable patient-side unit removes reprocessing between cases. Microbot is expanding clinical training and hospital adoption while gathering operating experience across its initial commercial sites.
Market context
DEPLOYMENT
Summary
Type: Surgical robotics
Core: LIBERTY
Function: Surgery
Audience: Healthcare providers
Products
- LIBERTY Endovascular Robotic System — surgical_robot
Research, Articles and recent verified events
- Microbot Medical adds Sanmina manufacturing capacity for LIBERTY — 2026-06-30
- Microbot Medical expands LIBERTY commercial footprint to seven Eastern U.S. states — 2026-06-23
- Microbot Medical adds first Michigan LIBERTY healthcare-system customer — 2026-06-09
- Microbot Medical secures first North Carolina LIBERTY customer — 2026-06-02
- Microbot Medical receives first international LIBERTY marketing approval — 2026-05-26
- Microbot Medical reports multiple LIBERTY account wins after full release — 2026-05-05
- Microbot Medical starts U.S. limited market release for LIBERTY — 2025-11-05
- Microbot Medical closes $25.2 million preferred-option exercise tranche — 2025-09-16